TI
ANIK icon

Trexquant Investment’s Anika Therapeutics ANIK Stock Holding History

Trexquant Investment’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$452K Sell
30,888
-33,165
-52% -$492K ﹤0.01% 1657
2026
Q1 		$929K Sell
64,053
-43,254
-40% -$502K 0.01% 1254
2025
Q4 		$1.03M Buy
107,307
+62,616
+140% +$600K 0.01% 1175
2025
Q3 		$420K Buy
+44,691
New +$427K ﹤0.01% 1355
2024
Q3 		– Sell
-17,899
Closed -$453K – 1510
2024
Q2 		$453K Sell
17,899
-18,902
-51% -$490K 0.01% 1276
2024
Q1 		$935K Sell
36,801
-21,662
-37% -$524K 0.02% 938
2023
Q4 		$1.32M Buy
58,463
+7,811
+15% +$162K 0.03% 718
2023
Q3 		$944K Buy
+50,652
New +$1.05M 0.02% 777
2023
Q1 		– Sell
-26,677
Closed -$790K – 1417
2022
Q4 		$790K Buy
26,677
+11,485
+76% +$327K 0.02% 738
2022
Q3 		$362K Sell
15,192
-5,966
-28% -$137K 0.01% 942
2022
Q2 		$472K Buy
21,158
+5,548
+36% +$124K 0.02% 856
2022
Q1 		$392K Buy
+15,610
New +$476K 0.02% 880
2021
Q3 		– Sell
-5,006
Closed -$217K – 1106
2021
Q2 		$217K Buy
+5,006
New +$213K 0.02% 871
2020
Q1 		– Sell
-10,283
Closed -$533K – 1077
2019
Q4 		$533K Buy
10,283
+4,463
+77% +$259K 0.03% 541
2019
Q3 		$319K Buy
+5,820
New +$299K 0.03% 598
2019
Q2 		– Sell
-11,820
Closed -$357K – 784
2019
Q1 		$357K Buy
+11,820
New +$405K 0.03% 683
2018
Q4 		– Sell
-5,403
Closed -$228K – 1016
2018
Q3 		$228K Buy
+5,403
New +$213K 0.02% 781
2017
Q2 		– Sell
-12,807
Closed -$556K – 776
2017
Q1 		$556K Buy
+12,807
New +$611K 0.07% 490
2015
Q4 		– Sell
-8,900
Closed -$283K – 989
2015
Q3 		$283K Buy
+8,900
New +$310K 0.02% 888
2015
Q1 		– Sell
-10,919
Closed -$444K – 973
2014
Q4 		$444K Buy
+10,919
New +$427K 0.08% 512

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Trexquant Investment's ANIK Position: Q2 2026 in Review

Trexquant Investment reduced its Anika Therapeutics (ANIK) stake by 52% in Q2 2026, selling an estimated $492K and leaving 30,888 shares worth $452K. The position accounts for ﹤0.01% of the portfolio, ranked #1657.

Trexquant Investment first reported a position in ANIK in Q4 2014 and has held it in 20 quarters since. The position peaked at $1.32M in Q4 2023. 134 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Trexquant Investment held 30,888 shares of Anika Therapeutics worth $452K as of Q2 2026.
  • Trexquant Investment sold 33,165 Anika Therapeutics shares in Q2 2026, an estimated $492K.
  • Anika Therapeutics made up ﹤0.01% of Trexquant Investment's portfolio in Q2 2026, its #1657 holding.
  • Trexquant Investment first reported a position in Anika Therapeutics in Q4 2014 and has held it in 20 quarters since.
  • Trexquant Investment's Anika Therapeutics position peaked at $1.32M in Q4 2023.
  • 134 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.